- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Theses and Dissertations /
- Study of serum inhibin levels in two in-vitro fertilization...
Open Collections
UBC Theses and Dissertations
UBC Theses and Dissertations
Study of serum inhibin levels in two in-vitro fertilization protocols Kwong, Eugene Cheuk Kun
Abstract
In order to characterize and compare the pattern of inhibin production in the follicular phase between patients of the clomiphene citrate/human menopausal gonadotropin (hMG) and Buserelin/hMG protocols in in-vitro fertilization, serum inhibin levels from 20 patients in each protocol were measured. The patients were matched for age and had tubal diseases only. It was hypothesized that the serum inhibin levels would be different in these two groups due to possible local actions of clomiphene citrate and Buserelin (a GnRH agonist) on the ovary. Serum inhibin levels were measured using an immunoenzymatic assay kit, with the mean interassay and intraassay coefficients of variation being 14.1% and 8.9% respectively. This assay did not cross-react with folliclestimulating hormone, luteinizing hormone, transforming growth factor β, activin A, insulin-like growth factor-1, seminal inhibin like peptide and human chorionic gonadotropin (hCG), but it could detect free a subunits of inhibin in addition to dimric inhibin. Apart from inhibin, serum estradiol-17/3 levels in patients from the two protocols were compiled from patient records. Serum inhibin was found to correlate significantly with serum estradiol-17/3 in the follicular phase (r= 0.844; P< 0.0001). In the clomiphene citrate/HMG protocol, on day 0 (day of ovulation trigger with hCG), day -1 (one day before hCG administration) and day -2 (two days before hCG administration), the serum inhibins were 6.84 +/- 0.76, 5.11 +/- 0.61, and 3.55 +/- 0.31 U/ml respectively; the serum estradiol-170 levels were 5141 +/- 353.6, 3332.7 +/- 192.6, and 2112.5 +/- 117.3 pmol/1 respectively. In the Buserelin/HMG protocol, on days 0, -1, and -2, the serum inhibin levels were 6.48 +/- 0.71, 5.47 +/- 0.49, and 4.0 +/- 0.35 U/ml respectively; the serum estradiol-17/3 levels were 4287.8 +/- 409.4, 2991.7 +/- 259.8, and 2093.5 +/- 151.3 pmol/1 respectively. Serum inhibin and estradiol-17/3 levels in these two protocols were compared by the unpaired t-test. No significant differences were found in serum inhibin and estradiol-17/3 levels on days 0, -1 and -2 between these two groups of patients (inhibin: P= 0.73, 0.639, and 0.37, respectively; estradiol-17/3: P= 0.123, 0.298 and 0.93, respectively). With respect to follicular growth as assessed by ultrasonography, the Buserelin/HMG protocol resulted in significantly greater number of large follicles with diameter greater than or equal to 17 mm on day 0 (2.45 +/- 0.28), compared with that in the corresponding size category of the clomiphene citrate/HMG protocol (1.50+/- 0.21) (P=0.0095). Whereas, in the size category of 10 to 13mm in follicular diameter on day 0, the number of follicles in the Buserelin/HMG protocol (4.7 + /- 0.7) was significantly smaller than that in the clomiphene citrate/HMG protocol (7.1 +/- 0.8) (P= 0.0306). Nevertheless, no significant differences were found in the number of oocytes retrieved, mature and total, between the two groups of patients. In summary, the clomiphene citrate/HMG and "ultra-short" Buserelin/HMG protocols resulted in similar ovarian responses as reflected by serum inhibin and estradiol-17/3 levels. Therefore, the data of the present study did not support the proposed hypothesis, despite the observation that the Buserelin/HMG protocol produced larger follicles.
Item Metadata
Title |
Study of serum inhibin levels in two in-vitro fertilization protocols
|
Creator | |
Publisher |
University of British Columbia
|
Date Issued |
1994
|
Description |
In order to characterize and compare the pattern of
inhibin production in the follicular phase between patients of
the clomiphene citrate/human menopausal gonadotropin (hMG) and
Buserelin/hMG protocols in in-vitro fertilization, serum
inhibin levels from 20 patients in each protocol were
measured. The patients were matched for age and had tubal
diseases only. It was hypothesized that the serum inhibin
levels would be different in these two groups due to possible
local actions of clomiphene citrate and Buserelin (a GnRH
agonist) on the ovary. Serum inhibin levels were measured
using an immunoenzymatic assay kit, with the mean interassay
and intraassay coefficients of variation being 14.1% and 8.9%
respectively. This assay did not cross-react with folliclestimulating
hormone, luteinizing hormone, transforming growth
factor β, activin A, insulin-like growth factor-1, seminal
inhibin like peptide and human chorionic gonadotropin (hCG),
but it could detect free a subunits of inhibin in addition to
dimric inhibin. Apart from inhibin, serum estradiol-17/3
levels in patients from the two protocols were compiled from
patient records. Serum inhibin was found to correlate
significantly with serum estradiol-17/3 in the follicular phase
(r= 0.844; P< 0.0001). In the clomiphene citrate/HMG
protocol, on day 0 (day of ovulation trigger with hCG), day -1
(one day before hCG administration) and day -2 (two days
before hCG administration), the serum inhibins were 6.84 +/- 0.76, 5.11 +/- 0.61, and 3.55 +/- 0.31 U/ml respectively; the
serum estradiol-170 levels were 5141 +/- 353.6, 3332.7 +/-
192.6, and 2112.5 +/- 117.3 pmol/1 respectively. In the
Buserelin/HMG protocol, on days 0, -1, and -2, the serum
inhibin levels were 6.48 +/- 0.71, 5.47 +/- 0.49, and 4.0 +/-
0.35 U/ml respectively; the serum estradiol-17/3 levels were
4287.8 +/- 409.4, 2991.7 +/- 259.8, and 2093.5 +/- 151.3
pmol/1 respectively. Serum inhibin and estradiol-17/3 levels
in these two protocols were compared by the unpaired t-test.
No significant differences were found in serum inhibin and
estradiol-17/3 levels on days 0, -1 and -2 between these two
groups of patients (inhibin: P= 0.73, 0.639, and 0.37,
respectively; estradiol-17/3: P= 0.123, 0.298 and 0.93,
respectively).
With respect to follicular growth as assessed by
ultrasonography, the Buserelin/HMG protocol resulted in
significantly greater number of large follicles with diameter
greater than or equal to 17 mm on day 0 (2.45 +/- 0.28),
compared with that in the corresponding size category of the
clomiphene citrate/HMG protocol (1.50+/- 0.21) (P=0.0095).
Whereas, in the size category of 10 to 13mm in follicular
diameter on day 0, the number of follicles in the
Buserelin/HMG protocol (4.7 + /- 0.7) was significantly smaller
than that in the clomiphene citrate/HMG protocol (7.1 +/- 0.8)
(P= 0.0306). Nevertheless, no significant differences were
found in the number of oocytes retrieved, mature and total, between the two groups of patients. In summary, the
clomiphene citrate/HMG and "ultra-short" Buserelin/HMG
protocols resulted in similar ovarian responses as reflected
by serum inhibin and estradiol-17/3 levels. Therefore, the
data of the present study did not support the proposed
hypothesis, despite the observation that the Buserelin/HMG
protocol produced larger follicles.
|
Extent |
4445422 bytes
|
Genre | |
Type | |
File Format |
application/pdf
|
Language |
eng
|
Date Available |
2009-03-03
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
For non-commercial purposes only, such as research, private study and education. Additional conditions apply, see Terms of Use https://open.library.ubc.ca/terms_of_use.
|
DOI |
10.14288/1.0087504
|
URI | |
Degree | |
Program | |
Affiliation | |
Degree Grantor |
University of British Columbia
|
Graduation Date |
1994-11
|
Campus | |
Scholarly Level |
Graduate
|
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
For non-commercial purposes only, such as research, private study and education. Additional conditions apply, see Terms of Use https://open.library.ubc.ca/terms_of_use.